Prof. Shuangbing Xu 徐双兵
Chief Physician, Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of thoracic tumors, including lung cancer, esophageal cancer, and mediastinal tumors, using radiotherapy, chemotherapy, immunotherapy, and molecular targeted therapy.
Dr. Xu is a Chief Physician, Professor, and doctoral supervisor at Union Hospital. Dr. Xu holds a PhD in Oncology from Sun Yat-sen University and completed postdoctoral training at MD Anderson Cancer Center. In 2017, Dr. Xu was selected for the Chinese Society of Clinical Oncology (CSCO) 35 under 35 list. Dr. Xu has led over 10 National Natural Science Foundation and provincial-level research projects.
Name order: in Chinese the family name comes first (Xu Shuangbing). Papers usually list the name as Shuangbing Xu or Xu S.
Selected publications
43 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Sci (Weinh), 2026 (senior author): UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD-L1 Transcription. PubMed 42325185
- Zhongguo Fei Ai Za Zhi, 2025 (senior author): [Ensartinib Combined with Radiotherapy for the Treatment of Advanced Primary Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring TPM3-ALK Fusion: A Case Report]. PubMed 41777067
- Oncogene, 2025 (senior author): Retraction Note: β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma. PubMed 40097808
- Curr Med Sci, 2025 (senior author): Efficacy and Safety of Third-Generation EGFR-TKIs Combined with Radiotherapy for Advanced NSCLC with Typical EGFR Mutations: A Retrospective Study. PubMed 40067564
- Cell Death Dis, 2024 (senior author): Correction: CDP138 silencing inhibits TGF-β/Smad signaling to impair radioresistance and metastasis via GDF15 in lung cancer. PubMed 39085215
- J Exp Clin Cancer Res, 2024 (senior author): CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer. PubMed 38520004
- Cell Death Discov, 2023 (senior author): KDM4C silencing inhibits cell migration and enhances radiosensitivity by inducing CXCL2 transcription in hepatocellular carcinoma. PubMed 37117173
- Cancer Lett, 2022 (senior author): Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer. PubMed 35149174
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion